Skip to main content

Table 2 Correlation of Parkin protein expression with clinical parameters among breast cancer patients

From: Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients

S. No. Variables Total Parkin Expressiona P valueb OR (95%CI)
Positive Negative
1 Age (Years) < 50 30 9 (30) 21 (70) 0.832 1.1255(0.4738–2.6737)
≥50 126 41 (33) 85 (67)
2 Weight (Kg) < 60 75 26 (35) 49 (65) 0.607 0.7935 (0.4046–1.5562)
≥60 81 24 (30) 57 (70)
3 Tumour size (cm) < 4’ 73 29 (40) 44 (60) 0.060 0.5139 (0. 2599–1.0161)
≥4 83 21 (25) 62 (75)
4 Clinical Stage I + II 88 29 (33) 59 (67) 0.863 0.9090 (0.4606–1.7941)
III + IV 68 21 (31) 47 (69)
5 Histologicalc grade WD 54 27 (50) 27 (50) 0.0001* 0.2911 (0.1435–0.5906)
MD + PD 102 23 (22) 79 (78)
6 Lymph Node Negative 81 39 (48) 42 (52) < 0.0001* 0.1851 (0.0854–0.4014)
Positive 75 11 (15) 64 (85)
7 Menopause Pre 38 18 (47) 20 (53) 0.028* 0.4134 (0.1943–0.8797)
Post 118 32 (27) 86 (73)
8 ERd Negative 81 23 (28) 58 (72) 0.391 1.9438 (0.0190–3.7081)
Positive 75 27 (36) 48 (64)
9 PRe Negative 103 32 (31) 71 (69) 0.721 1.1411 (0.5637–2.3099)
Positive 53 18 (34) 35 (66)
10 Her-2f Negative 111 36 (32) 75 (68) 1.000 0.9409 (0.4463–1.9835)
Positive 45 14 (31) 31 (69)
11 TNBCg No 106 42 (40) 64 (60) 0.003* 0.2902 (0.1240–0.6793)
Yes 50 8 (16) 42 (84)
  1. a Protein expression through IHC (Immunohistochemistry)
  2. b Fisher’s exact test, *Significant Correlation (P < 0.05)
  3. c WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated
  4. d Estrogen receptor
  5. e Progesterone receptor
  6. f human epidermal growth factor receptor 2
  7. g Triple Negative breast cancer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us